About Leucine-rich repeat neuronal protein 4
Leucine-rich repeat neuronal protein 4 (LRRN4) is a protein
from Homo sapiens identified by UniProt accession
Q8WUT4, 740 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | Leucine-rich repeat neuronal protein 4 |
|---|
| UniProt accession | Q8WUT4 |
|---|
| Gene | LRRN4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 740 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8WUT4-F1 | alphafold | PREDICTED | 69.42 | — |
Amino-acid sequence (740 residues)
MRQTLPLLLL TVLRPSWADP PQEKVPLFRV TQQGPWGSSG SNATDSPCEG LPAADATALT LANRNLERLP GCLPRTLRSL DASHNLLRAL STSELGHLEQ LQVLTLRHNR IAALRWGPGG PAGLHTLDLS YNQLAALPPC TGPALSSLRA LALAGNPLRA LQPRAFACFP ALQLLNLSCT ALGRGAQGGI AEAAFAGEDG APLVTLEVLD LSGTFLERVE SGWIRDLPKL TSLYLRKMPR LTTLEGDIFK MTPNLQQLDC QDSPALASVA THIFQDTPHL QVLLFQNCNL SSFPPWTLDS SQVLSINLFG NPLTCSCDLS WLLTDAKRTV LSRAADTMCA PAAGSSGPFS ASLSLSQLPG VCQSDQSTTL GASHPPCFNR STYAQGTTVA PSAAPATRPA GDQQSVSKAP NVGSRTIAAW PHSDAREGTA PSTTNSVAGH SNSSVFPRAA STTRTQHRGE HAPELVLEPD ISAASTPLAS KLLGPFPTSW DRSISSPQPG QRTHATPQAP NPSLSEGEIP VLLLDDYSEE EEGRKEEVGT PHQDVPCDYH PCKHLQTPCA ELQRRWRCRC PGLSGEDTIP DPPRLQGVTE TTDTSALVHW CAPNSVVHGY QIRYSAEGWA GNQSVVGVIY ATARQHPLYG LSPGTTYRVC VLAANRAGLS QPRSSGWRSP CAAFTTKPSF ALLLSGLCAA SGLLLASTVV LSACLCRRGQ TLGLQRCDTH LVAYKNPAFD DYPLGLQTVS
Explore Leucine-rich repeat neuronal protein 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets